Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XH02 in Adult Hypoparathyroidism
NCT07197450Phase 1Suspended
- Sponsor
- Peking Union Medical College Hospital
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of XH02 in hypoparathyroidism (5 arms), sponsored by Peking Union Medical College Hospital. Primary endpoint: Adverse Events and Serious Adverse Events at 90 days. Started May 2025; status: suspended.
02
Drugs
XH02
03
Conditions
hypoparathyroidism
Beyond the preview
Go deeper on NCT07197450.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07197450.